Experimental studies using animal NASH models suggested a favorable effect of SGLT-2 inhibitors on liver steatosis, inflammation, and fibrosis owing to a combination of negative energy balance by increased glycosuria and substrate switching toward lipids as a source of energy expenditure [102]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.